← Leaderboards
Bianca Diaz
Weill Medical Coll Of Cornell Univ
$189,456
Attributed
$189,456
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $49K · FY2021–24$50K$37.5K$25K$12.5K$0
'21
'22
'23
'24
Funding mix
By agency
NIH$189,456 · 1
By mechanism
F31$189,456 · 1
Top collaborators
No co-investigators on record.
Most similar at Weill Medical Coll Of Cornell Univ
Same institution · by research overlap
- Sarah Marie Cheal$3,628,213
- Jorge Moscat$21,067,408
- Dingcheng Gao$4,134,819
- Yi-Chieh Nancy Du$3,693,887
- Joyce Huanhuan Chen$1,630,227
Others in their field
Other Emerging Leaders on “Combined Modality Therapy”
- Barbara Burtness · Yale University$11,235,253
- Jurgen Bernd Bulitta · State University Of New York At Buffalo$7,090,719
- Kathleen N. Moore · University Of Oklahoma$6,686,608
- Nilu Goonetilleke · Univ Of North Carolina Chapel Hill$6,073,977
- Feixiong Cheng · Cleveland Clinic Lerner Com-Cwru$5,834,007
- Nader Fotouhi · Global Alliance For Tb Drug Development$5,472,466
Research focus
Combined Modality TherapyAffectCodon NucleotidesCohortAllelesBindingAftercareAllelic ImbalanceApoptosisCancer EtiologyCancer PatientCancer TypeCdkn2a GeneCell GrowthCell NucleusBiologyCessation Of LifeChemotherapyClinicCancer Cell LineClinically RelevantClinical ManagementClustered Regularly Interspaced Short Palindromic RepeatsCrispr Library
Grant awards (4)
Interrogating the role of mutant KRAS allelic imbalance and co-mutated genes in targeted therapy response of NSCLC$48,974
F31 · FY2024 · CA · contact PI
Interrogating the role of mutant KRAS allelic imbalance and co-mutated genes in targeted therapy response of NSCLC$47,694
F31 · FY2023 · CA · contact PI
Interrogating the role of mutant KRAS allelic imbalance and co-mutated genes in targeted therapy response of NSCLC$46,752
F31 · FY2022 · CA · contact PI
Interrogating the role of mutant KRAS allelic imbalance and co-mutated genes in targeted therapy response of NSCLC$46,036
F31 · FY2021 · CA · contact PI